/ / / Diagnostyka as MedApp partner

Diagnostyka as MedApp partner

strzykawka badanie reka

Ten post jest także dostępny w języku: polski

MedApp S.A. develops the Digital Clinic service. As part of this, the company signed a partnership agreement with the largest network of diagnostic laboratories in Poland – Diagnostyka company. The cooperation between the two companies is intended to allow patients and doctors remote access to the results of examinations carried out by Diagnostyka.

Laboratory examinations in MedApp Digital Clinic

MedApp has announced that entering into a partnership with the leader in laboratory diagnostics in Poland is an important step in the development of the company’s Digital Clinic. The partnership will enable specialists from medical institutions to remotely order laboratory tests, which are carried out by the Diagnostyka network. Importantly, the solution gives both doctors and patients the opportunity to check the results online.

Let us remind that Diagnostyka is the biggest network of medical laboratories in Poland which has been operating since 1998. The company specialises in the realisation of professional services from the collection and transport of biological material, through the performance of the test, to the delivery of the results of medical analyses.

MedApp targets further growth

The new MedApp service is an extension of the existing range of tools and solutions available in the CarnaLife System app. In 2020. The company significantly expanded sales in the country, and this year plans to further develop it in other European countries as well. To this end, MedApp signed an agreement with Insight Direct in the UK in January 2021. There, the company will distribute, among other things, the CarnaLife Holo 3D holographic imaging technology used in cardiology, oncology and orthopaedic procedures.

It is worth noting that in 2020, MedApp’s revenues exceeded PLN 6m, an increase of 187% compared to 2019 results. The company said that in 2021 it plans, among other things, to move its listing to the main market of the WSE, to further increase the scale of its operations and financial results while expanding the distribution of its products in Europe and preparing to obtain FDA certification in the US.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *